Ratings Beijing Labtech Instruments Co., Ltd.

Equities

688056

CNE1000043C6

End-of-day quote Shanghai S.E. 06:00:00 2024-06-03 pm EDT 5-day change 1st Jan Change
22.29 CNY -4.70% Intraday chart for Beijing Labtech Instruments Co., Ltd. -8.16% -33.48%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.

Weaknesses

  • The firm trades with high earnings multiples: 26.38 times its 2024 earnings per share.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Office Equipment

1st Jan change Capi. Investor Rating ESG Refinitiv
-33.48% 217M -
+4.77% 7.73B
B-
-6.99% 4.59B
B
-2.72% 2.99B -
+8.51% 2.21B -
-31.85% 1.05B -
+16.32% 1.05B
C+
+8.13% 914M -
-51.71% 800M -
-19.42% 722M - -
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 688056 Stock
  4. Ratings Beijing Labtech Instruments Co., Ltd.